Eisai Co's Total Assets for the quarter that ended in Mar. 2026 was $9,132 Mil.
During the past 12 months, Eisai Co's average Total Assets Growth Rate was 7.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 6.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 7.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 4.90% per year.
During the past 13 years, Eisai Co's highest 3-Year average Total Assets Growth Rate was 24.70%. The lowest was -6.40%. And the median was 4.75%.
Total Assets is connected with ROA %. Eisai Co's annualizedROA % for the quarter that ended in Mar. 2026 was -0.88%. Total Assets is also linked to Revenue through Asset Turnover. Eisai Co's Asset Turnover for the quarter that ended in Mar. 2026 was 0.14.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Eisai Co's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Eisai Co Total Assets Related Terms
Eisai Co Total Assets Historical Data
* Premium members only.
The historical data trend for Eisai Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Eisai Co's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (ESALF) has a Total Assets of $9,132 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Eisai Co and its competitors.
Is Eisai Co's Total Assets too high?
Eisai Co's current Total Assets is $9,132 Mil. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Total Assets compare to ZTS?
Eisai Co's Total Assets of $9,132 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Eisai Co and its competitors. Eisai Co's current Total Assets is $9,132 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $35.06, compared to a current price of $25.00 — trading 28.7% below its estimated fair value. The current Total Assets is $9,132 Mil. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Eisai Co (ESALF), the current Total Assets is $9,132 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $25.00 is trading 28.7% below its estimated GF Value™ of $35.06.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for ESALF:
Total Assets: $9,132 Mil
GF Value™: $35.06 vs. price of $25.00 (28.7% below fair value)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score
Get the complete analysis for ESALF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
